Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P5G1 | ISIN: US45258J1025 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
16,765 US-Dollar
+4,65 % +0,745
1-Jahres-Chart
IMMUNOVANT INC Chart 1 Jahr
5-Tage-Chart
IMMUNOVANT INC 5-Tage-Chart

Aktuelle News zur IMMUNOVANT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.05.IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus2
30.05.Immunovant stock price target cut to $35 at H.C. Wainwright1
29.05.Immunovant, Inc. - 10-K, Annual Report2
29.05.Immunovant GAAP EPS of -$0.64 beats by $0.061
IMMUNOVANT Aktie jetzt für 0€ handeln
29.05.Immunovant, Inc. - 8-K, Current Report2
29.05.Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 202594Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)...
► Artikel lesen
30.04.Immunovant, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
21.04.Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift4
21.04.Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts1
21.04.Immunovant makes leadership changes2
21.04.Immunovant, Inc. - 8-K, Current Report2
21.04.Immunovant Inc.: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402266Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO...
► Artikel lesen
21.04.Roivant Sciences: Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-14021
20.03.Stifel raises Immunovant stock price target to $61 from $582
20.03.IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success1
20.03.Immunovant stock holds $51 target on positive trial data5
20.03.Oppenheimer maintains $54 target on Immunovant stock2
20.03.Citi maintains Buy on Immunovant stock with $58 target2
19.03.Immunovant claims study success for immune disease drug but holds off on submission1
19.03.Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data2
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1